Surveillance of resistance in bacteria causing community-acquired respiratory tract infections

Clinical Microbiology and Infection

Volumn 8, Issue SUPPL. 2, 2002, Pages 12-42

  Felmingham, D ^a   Feldman, C ^b   Hryniewicz, W ^c   Klugman, K ^d   Kohno, S ^e   Low, D E ^f   Mendes, C ^g   Rodloff, A C ^h  

^a GR Micro Ltd   (United Kingdom)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Sera & Vaccines Central Research Laboratory Warszawa   (Poland)

^d EMORY UNIVERSITY   (United States)

^e NAGASAKI UNIVERSITY   (Japan)

^f MOUNT SINAI HOSPITAL   (Canada)

^g Fleury   (Brazil)

^h UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antimicrobial resistance; Global situation; Respiratory tract pathogens; Surveillance principles and practice

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; MIKAMYCIN B; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SPIRAMYCIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ACCURACY; AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASIA; BACTERIAL STRAIN; CENTRAL AMERICA; COMMUNITY; CONTROLLED STUDY; DEVELOPING COUNTRY; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; DRUG USE; EASTERN EUROPE; EPIDEMIOLOGICAL DATA; EUROPE; GENETIC RESISTANCE; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RESPIRATORY TRACT INFECTION; REVIEW; STANDARDIZATION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES; VALIDATION PROCESS; WESTERN HEMISPHERE;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0036400469     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.8.s.2.5.x     Document Type: Article

References (192)

1. Macris MH, Hartman N, Murray B et al. Studies of the continuing susceptibility of group A streptococcal strains to penicillin during eight decades. Pediatr Infect Dis J 1998; 17: 377-81.
2. Horn DL, Zabriskie JB, Austrian R et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 1998; 26: 1341-5.
3. Widdowson CA, Klugman KP. Molecular mechanisms of resistance to commonly used non-β-lactam drugs in Streptococcus pneumoniae. Semin Respir Infect 1999; 14: 255-68.
4. McGee L, Klugman KP, Wasas A, Capper T, Brink A. The Antibiotics Surveillance Forum of South Africa. Serotype 19F multiresistant pneumococcal clone harboring two erythromycin resistance determinants [erm (b) and mef (a) ] in South Africa. Antimicrob Agents Chemother 2001; 45: 1595-8.
5. Corso A, Severina EP, Petruk VF, Mauriz YR, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4: 325-37.
6. Richter SS, Heilmann KP, Coffman SL et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis 2002; 34: 330-9.
7. Ho PL, Yam WC, Cheung TKM et al. Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerg Infect Dis 2001; 7: 906-8.
8. McGee L, Goldsmith CE, Klugman KP. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother 2002; 49: 173-6.
9. Scriver SR, Walmsley SL, Kau CL et al. Determination of antimicrobial susceptibility of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrob Agents Chemother 1994; 38: 1678-80.
10. Bootsma HJ, van Dijk H, Vauterin P, Verhoef J, Mooi FR. Genesis of BRO beta-lactamase-producing Moraxella catarrhalis: evidence for transformation-mediated horizontal transfer. Mol Microbiol 2000; 36: 93-104.
11. European Commission. Communication from the Commission on a Community Strategy Against Antimicrobial Resistance [COM 2001, 3331]. Brussels. Commission of the European Communities. (http://europa.eu.International).
12. World Health Organization. Report on Infectious Diseases 2000: Overcoming Antimicrobial Resistance. Geneva: World Health Organization, 2000; (http:// www.who.International/infectious-disease-report/ 2000/index.html).
13. Interagency Task Force on Antimicrobial Resistance. Public Health Action Plan to Combat Antimicrobial Resistance. Atlanta: Centers for Disease Control and Prevention, 2001.
14. Bax R, Bywater R, Cornaglia G et al. Surveillance of antimicrobial resistance-what, how and whither? Clin Microbiol Infect 2001; 7: 316-25.
15. Lewis D. Antimicrobial resistance surveillance: methods will depend on objectives. J Antimicrob Chemother 2002; 49: 3-5.
16. Morris AK, Masterton RG. Antibiotic resistance surveillance: action for international studies. J Antimicrob Chemother 2002; 49: 7-10.
17. Monnet DL. Toward multinational antimicrobial resistance surveillance systems in Europe. Int J Antimicrob Agents 2000; 15: 91-100.
18. Thacker SB. Surveillance. In: Gregg, MB, ed. Field Epidemiology. Oxford: Oxford University Press, 1996; 16-32.
19. Masterton RG. Surveillance studies. how can they help the management of infection? J Antimicrob Chemother 2000; 46(Suppl. T2): 53-8.
20. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996. J Chemother 1999; 11(Suppl. 1): 5-21.
21. Felmingham D, Grüneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
22. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program 1997-1999. Clin Infect Dis 2001; 32(Suppl. 2): S81-S93.
23. NCCLS. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard, 7th edn M2-A7. Pennsylvania: National Committee for Clinical Laboratory Standards, 2000.
24. NCCLS. Performance Standards for Antimicrobial Disk Susceptibility Tests; eleventh informational, M100-S11. Pennsylvania: National Committee for Clinical Laboratory Standards, 2001.
25. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 2001; 7: 319-22.
26. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. J Infect 2002; 44(Suppl. A): 3-10.
27. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network Database - USA. Clin Infect Dis 1999; 29: 259-63.
28. Archibald LK, Reller BL. Clinical microbiology in developing regions. Emerg Infect Dis 2001; 7: 302-5.
29. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis 1997; 24(Suppl. 1): S157-68.
30. Jacobs MR. Assessing the quality of the Alexander Project. J Chemother 1999; 11: 26-34.
31. Finch RG, Low DE. A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8(Suppl. 2): 69-91.
32. Deeks SL, Palacio R, Ruvinsky R et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999; 103: 409-13.
33. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am J Med 2001; 111(Suppl. 9A): 19S-24S.
34. Wald ER, Mason EO Jr, Bradley JS et al. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997. Pediatr Infect Dis J 2001; 20: 34-9.
35. Samore MH, Magill MK, Alder SC et al. High rates of multiple antibiotic resistance in Streptococcus pneumoniae in healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission. Pediatrics 2001; 108: 856-65.
36. Leegaard TM, Caugant DA, Frøholm LO, Høiby EA. Apparent differences in antimicrobial susceptibility as a consequence of national guidelines. Clin Microbiol Infect 1997; 6: 290-3.
37. Kiehlbauch JA, Hannett GE, Salfinger M, Archinal W, Monserrat C, Carlyn C. Use of the National Committee for Clinical Laboratory Standards guidelines for disk diffusion susceptibility testing in New York State laboratories. Clin Infect Dis 2001; 38: 3341-8.
38. Baquero F. Towards standards for antibiotic susceptibility testing: towards a theoretical consensus. Eur J Clin Microbiol Infect Dis 1990; 9: 492-5.
39. Phillips I, King A. Standardization of susceptibility testing methods. J Chemother 1997; 9: 13-18.
40. Andrews JM. The development of the BSAC standardized method of disc diffusion testing. J Antimicrob Chemother 2001; 48(Suppl. A): 29-42.
41. Andrews JM, BSAC Working Party On Susceptibility Testing ft. BSAC standardized disc susceptibility testing method. J Antimicrob Chemother 2001; 48(Suppl. A): 43-57.
42. EUCAST. Definitive document E. Def 1.2. Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503-8.
43. EUCAST. Definitive document E. Def 3.1. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microbiol Infect 2000; 6: 509-15.
44. EUCAST. Definitive document E. Def 2.1. Determination of antimicrobial susceptibility test break-points. Clin Microbiol Infect 2000; 6: 570-2.
45. Felmingham D, Brown DFJ. Instrumentation in antimicrobial susceptibility testing. J Antimicrob Chemother 2001; 48(Suppl. S1): 81-5.
46. Tenover FC, Mohammed MJ, Stelling J, O'Brien T, Williams R. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's External Quality Assurance System for Antimicrobial Susceptibility Testing. J Clin Microbiol 2001; 39: 241-50.
47. Jorgensen JH, Swenson JM, Tenover FC et al. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol 1996; 34: 2679-84.
48. MacGowan AP, Wise R. Establishing MIC break-points and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48(Suppl. S1): 17-28.
49. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect 2002; 8(Suppl. 2): 1-11.
50. Jones RN. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. J Antimicrob Chemother 2000; 46(Suppl. T2): 1-8.
51. Finch RG. Antibiotic resistance. J Antimicrob Chemother 1998; 42: 125-8.
52. Reeves DS. Antimicrobial resistance surveillance: current initiatives are not enough. J Antimicrob Chemother 2002; 49: 1.
53. Marchese A, Schito GC. Role of global surveillance in combating bacterial resistance. Drugs 2001; 61: 167-73.
54. Carbon C, Cars O, Christiansen K. Moving from recommendation to implementation and audit: Part 1. Current recommendations and programs: a critical commentary. Clin Microbiol Infect 2002; 8(Suppl. 2): 92-106.
55. Christiansen K, Carbon C, Cars O. Moving from recommendation to implementation and audit: Part 2. Review of interventions and audit. Clin Microbiol Infect 2002; 8(Suppl. 2): 107-128.
56. PROTEKT Study Database. Feb. 2001 (http:http:// www.protekt.org).
57. Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-98. J Antimicrob Chemother 2000; 45: 457-66.
58. Garcia-Martos P, Galán F, Marin P, Mira J. Increase in high resistance to penicillin of clinical isolates of Streptococcus pneumoniae in Cd́iz, Spain. Chemotherapy 1997; 43: 179-81.
59. Hermans PW, Sluijter M, Dejsirilert S et al. Molecular epidemiology of drug-resistant pneumococci: toward an international approach. Microb Drug Resist 1997; 3: 243-51.
60. Goldsmith CE, Moore JE, Murphy PG. Pneumococcal resistance in the UK. J Antimicrob Chemother 1997; 40(Suppl. A): 11-18.
61. Reinert RR, Simic S, Al Lahharn A, Reinert S, Lemperle M, Lutticken R. Antimicrobial resistance of Streptococcus pneumoniae recovered from out-patients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J Clin Microbiol 2001; 39: 1187-9.
62. Nissinen A, Leinonen M, Huovinen P et al. Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990. Clin Infect Dis 1995; 20: 1275-80.
63. Manninen R, Huovinen P, Nissinen A. Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland. J Antimicrob Chemother 1997; 40: 387-92.
64. Örtqvist Å. Pneumococcal disease in Sweden: experiences and current situation. Am J Med 1999; 107(Suppl. 1A): 44S-9S.
65. Henning C, Bengtsson L, Jorup C, Engquist S. Antibiotic resistance in Streptococcus pneumonia, Haemophilus influenzae and Streptococcus pyogenes in respiratory tract infections in outpatients. Scand J Infect Dis, 1997; 29: 559-63.
66. Kamme C, Ekdahl K, Mölstad S. Penicillin-resistant pneumococci in Southern Sweden, 1993-1997. Microb Drug Resist 1999; 5: 31-6.
67. Kristinsson KG. Epidemiology of penicillin resistant pneumococci in Iceland. Microb Drug Resist 1995; 1: 121-5.
68. Baquero F, Garcia-Rodriguez JA, Garcia dL, Aguilar L. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999; 43: 357-9.
69. Cornaglia G, Fontana R. Epidemiological survey of bacterial resistance in upper respiratory tract infections in Italy. Int J Antimicrob Agents 2000; 16: 259-62.
70. Oster P, Zanchi A, Cresti S et al. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother 1999; 43: 2510-12.
71. Descheemaeker P, Chapelle S, Larnmens C et al. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother 2000; 45: 167-73.
72. Granizo JJ, Aguilar L, Casal J, Garcia-Rey C, Dal Ré R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 46: 767-73.
73. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother, 2000; 46(Suppl. T1): 3-9.
74. Baquero F, Negri MC. Strategies to minimize the development of antibiotic resistance. J Chemother 1997; 9(Suppl. 3): 27-37.
75. Felmingham D, Grüneberg RN. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. J Antimicrob Chemother 1996; 38(Suppl. A): 1-57.
76. Lowbury EJL. Symposium on epidemiological risks of antibiotics. Hospital infections. Proc R Soc Med 1958; 51: 807-10.
77. Melo-Cristino J, Fernandes ML. Streptococcus pyogenes isolated in Portugal: macrolide resistance phenotypes and correlation with T types. Portuguese Surveillance Group for the Study of Respiratory Pathogens. Microb Drug Resist 1999; 5: 219-25.
78. Alós JI, Aracil B, Oteo J, Torres C, Gómez-Garcés JL. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting. J Antimicrob Chemother 2000; 45: 605-9.
79. Baquero F, Garcia-Rodriguez JA, de Lomas JG, Aguilar L. Antimicrobial resistance of 914 betahemolytic streptococci isolated from pharyngeal swabs in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 1999; 43: 178-80.
80. Bingen E, Fitoussi F, Doit C et al. Resistance to macrolides; in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother 2000; 44: 1453-7.
81. Seppälä H, Nissinen A, Järvinen H et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326: 292-7.
82. Seppälä H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med, 1997; 337: 441-6.
83. Granizo JJ, Aguilar L, Casal J, Dal Re R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother 2000; 46: 959-64.
84. Bassetti M, Manno G, Collida A et al. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis 2000; 6: 180-3.
85. Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851-3.
86. Felmingham D, Grüneberg RN, and the Alexander Project Group. The Alexander Project 1999 preliminary results: penicillin and macrolide resistance in Streptococcus pneumoniae. Abstract and poster (P1790). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. 2000.
87. Hryniewicz W. Bacterial resistance in Eastern Europe - selected problems. Scand J Infect Dis Suppl 1994; 93: 33-9.
88. Betlejewska K, Hryniewicz W. Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland. Int J Antimicrob Agents 2002; 19: 47-52.
89. Sidorenko SV, Grudinina SA, Kotosova LK. Antimicrobial resistance of Streptococcus pneumoniae recovered from respiratory tract infections (RTI) of inpatients in Moscow. Abstract (P1791). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada. 2000.
90. Stratchounski LS, Kretchikova. OI, Kozlov RS et al. Antimicrobial resistance of Streptococcus pneumoniae isolated from healthy children in day-care centers: results of a multicenter study in Russia. Pediatr Infect Dis J 2000; 19: 196-200.
91. Naaber P, Tamm E, Putsepp A, Koljalg S, Maimets M. Nasopharyngeal carriage and antibacterial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Estonian children. Clin Microbiol Infect 2000; 6: 675-7.
92. Marton A, Mezzner Z. Epidemiological studies on drug resistance in Streptococcus pneumoniae in Hungary. An update for the 1990s. Microb Drug Resist 1999; 5: 201-5.
93. Stratchounski L, Bedenkov A, Hryniewicz W, Kremery V, Ludwig E, Semenov V. The usage of antibiotics in Russia and some countries in Eastern Europe. Int J Antimicrob Agents 2001; 18: 283-6.
94. Kremery V, Jeljaszewicz J, Grzesiowski P et al. National and local antibiotic policies in Central and Eastern Europe. J Chemother 2000; 12: 471-4.
95. Stephenson WP, Doern G, Gantz N, Lipworth L, Chapin K. Pharyngeal carriage rates of Haemophilus influenzae, type b and non-b, and prevalence of ampicillin-resistant Haemophilus influenzae among healthy day-care children in central Massachusetts. Am J Epidemiol 1985; 122: 868-75.
96. Nash DR, Wallace RJ Jr, Steingrube VA, Shurin PA. Isoelectric focusing of beta-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States. Drugs 1986; 31(Suppl. 3): 48-54.
97. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis 1991; 163: 1273-8.
98. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271: 1831-5.
99. Biedenbach DJ, Jones RN, Pfaller MA. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagn Microbiol Infect Dis 2001; 39: 245-50.
100. Sahm DF, Karlowsky JA, Kelly LJ et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001; 45: 1037-42.
101. Hoban DJ, Wierzbowski AK, Nichol K, Zhanel GG. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-99. Prevalence of mef(a) and erm(B) and susceptibilities to ketolides. Antimicrob Agents Chemother 2001; 45: 2147-50.
102. Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-24.
103. Chen D, McGeer A, de Azavedo JC. Low DE, The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Eng J Med 1999; 341: 233-9.
104. Dixon JM, Lipinski AE, Graham ME. Detection and prevalence of pneumococci with increased resistance to penicillin. Can Med Assoc J 1977; 117: 1159-61.
105. Jette LP, Lamothe F. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol, 1989; 27: 1-5.
106. Simor AE, Louie M, Low DE. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother 1996; 40: 2190-3.
107. Zhanel GG, Karlowsky JA, Palatnick L, Vercaigne L, Low DE, Hoban DJ. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group. Antimicrob Agents Chemother 1999; 43: 2504-9.
108. Davidson RJ, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med, 2002; 346: 747-50.
109. McGeer A, Green K, Trpeski L et al. Decreasing antibiotic resistance in Streptococcus pneumoniae: What is the driving force? Abstract (P1796). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada. 2000.
110. Low DE, de Azavedo J, Weiss CA et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002; 46: 1295-301.
111. Maki DG, Helstad AG, Kimball JL. Penicillin susceptibility of Streptococcus pneumoniae in 1978. Screening for Resistance by Disk Testing. Am J Clin Pathol 1980; 73: 177-82.
112. Centers for Disease Control and Prevention. Drug-resistant Streptococcus pneumoniae - Kentucky and Tennessee, 1993. JAMA 1994; 271: 421-2.
113. Doern GV, Brueggemann A, Holley HPJ, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-13.
114. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 1998; 27: 764-70.
115. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45: 1721-9.
116. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with streptococcus pneumoniae in the United States, 1997-98. Emerg Infect Dis 1999; 5: 757-65.
117. Bush K. Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'. Antimicrob Agents Chemother 1989; 33: 264-70.
118. Daum RS, Murphey-Corb M, Shapira E, Dipp S. Epidemiology of ROB beta-lactamase among ampicillin-resistant Haemophilus influenzae isolates in the United States. J Infect Dis 1988; 157: 450-5.
119. Doern GV, Brueggemann AB, Pierce G, Holley HP Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997; 41: 292-7.
120. Doern GV, Jones RN, Waller MA, Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections. antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1999; 43: 385-9.
121. Bannatyne RM, Toma S, Cheung R, Hodge D. Antibiotic susceptibility of blood and cerebrospinal fluid isolates of Haemophilus influenzae. J Antimicrob Chemother 1985; 15: 187-91.
122. Hoban DJ, Zhanel GG, Karlowsky JA. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1999; 35: 37-44.
123. Zhanel GG, Karlowsky JA, Low DE, Hoban DJ. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998. Canad In J Antimicrob Chemother 2000; 45: 655-62.
124. Low DE. Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin Infect Dis 2002; 33(Suppl. 3): S206-13.
125. Doern GV, Jorgensen JH, Thornsberry C, Preston DA. Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis 1986; 4: 95-107.
126. Doern GV, Jorgensen JH, Thornsberry C et al. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother 1988; 32: 180-5.
127. Doern GV, Brueggemann AB, Pierce G, Holley HP Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997; 41: 292-7.
128. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997; 29: 249-57.
129. Richter SS, Brueggemann AB, Huynh HK et al. A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US Institutions. Int J Antimicrob Agents 1999; 13: 99-107.
130. Doern GV, Chapin KC. Susceptibility of Haemophilus influenzae to amoxicillin/clavulanic acid, erythromycin, cefaclor, and trimethoprim/sulfa-methoxazole. Diagn Microbiol Infect Dis 1986; 4: 37-41.
131. Percival A, Corkill JE, Rowlands J, Sykes RB. Pathogenicity of and beta-lactamase production by Branhamella (Neisseria) catarrhalis. Lancet, 1977; 2: 1175.
132. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J 1999; 18: 1069-72.
133. de Azavedo JC, Yeung RH, Bast DJ, Duncan CL, Borgia SB, Low DE. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Chemother 1999; 43: 2144-7.
134. Lovinsky A, Low DE. Emergence of macrolide resistance in Group A streptococci causing invasive disease in Ontario, Canada 1992-2000 Abstract (CS-321). Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001.
135. Weiss K, de Azavedo J, Restieri C et al. Phenotypic and genotypic characterization of macrolide-resistant group A streptococcus strains in the province of Quebec, Canada. J Antimicrob Chemother 2001; 47: 345-8.
136. York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 1999; 37: 1727-31.
137. Jacobs MR, Appelbaum PC. Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries. Laser Study Group Int J Antimicrob Agents 2000 1997; 16: 17-24.
138. Odland BA, Jones RN, Verhoef J, Fluit A, Beach ML. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe). Diagn Microbiol Infect Dis 1999; 34: 315-20.
139. Sader HS, Gales AC, Reis AO, Zoccoli C, Sampaio J, Jones RN. Sensibilidade a antimicrobianos de bactérias isoladas do trato respiratório de pacientes com infecções do trato respiratório adquiridas na Ccmunidade - resultados Brasileiros do programa SENTRY de vigilância de resistência a antimicrobianos dos anos de 1997 e 1998. Jornal Pneumol 2001; 27: 25-34.
140. Orrantia-Gradin RD, Silva H, Pontani D and Latin American Artemis study group. El proyecto Artemis. Un estudio sobre la actividad de algunos antibioticos de uso comum para el tratamiento de las infecciones del tracto respiratorio en diez paises latinoamericanos. Rev Panam Infectol 1998; 2: 68-75.
141. Sader HS, Jones RN, Ballow CH, Biedenbach DJ, Cered RF and the GSMART Latin America Study Group. Antimicrobial susceptibility of quinupristin /dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study. Braz J Infect Dis 2001; 5: 21-31.
142. Mendes C, Sader H, Dainesi SM et al. Evaluation of the antimicrobial activity of sparfloxacin, relative to other oral antibiotics against 1,125 bacterial isolates from 10 medical centers in Brazil. Braz J Infect Dis, 1998; 2: 18-24.
143. Critchley IA, Hickey ML, Barth AL et al. Antimicrobial resistance surveillance of 1997-1998 isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis from Brazil. Abstract (A89) presented at the 99th General Meeting of the American Society for Microbiology, 1997-98 1999.
144. Sader HS, Gales AC, Granacher TD, Pfaller MA, Jones RN and the SENTRY Study Group (Latin America). Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98). Braz J Infect Dis 2000; 4: 245-54.
145. Hortal M, Ruvinsky R, Rossi A, Agudelo CI et al. Impact of Streptococcus pneumoniae on pneumonia in Latin American children. SIREVA-Vigía Group. Rev Panam Salud Publica 2000; 8: 185-95.
146. Mendes C, Sinto S, Hsiung A et al. Antimicrobial in vitro activity of quinupristin/dalfopristin against Gram-positive cocci isolated from 5 Brazilian centers: results from the Local SMART (LSMART) surveillance study. J Bras Patol Clin 2002; 38: 3.
147. Rossi A, Tokumoto M, Galas M, Soloaga R, Corso A. Monitoring antibiotic resistance in Argentina. The WHONET Program, 1995-1996. Rev Panam Salud Publica 1999; 6: 234-41.
148. Mendes C, Sinto S, Hsiung A et al. 'In-vitro' evaluation of macrolides and β-lactam antibiotics against respiratory-tract microorganisms. Rev Bras Med 2002; 59: 63-8.
149. Song JH, Lee NY, Ichiyama S et al. Spread of drug-resistant Streptococcus pneumoniae in Asian Countries. Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis 1999; 28: 1206-11.
150. Yoshida R, Kaku M, Kohno S et al. Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrob Agents Chemother 1995; 39: 1196-8.
151. Ikemoto H, Ito C, Yoshida T et al. Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1998) [in Jap]. Jpn J Antibiot 2000; 53: 261-98.
152. Wang H, Heubner R, Chen M, Klugman K. Antibiotic susceptibility patterns of Streptococcus pneumoniae in China and Comparison of MICs by Agar Dilution and E-Test Methods. Antimicrob Agents Chemother 1998; 42: 2633-6.
153. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310-13.
154. Chang SC, Hsieh WC, Liu CY. High prevalence of antibiotic resistance of common pathogenic bacteria in Taiwan. The Antibiotic Resistance Study Group of the Infectious Disease Society of the Republic of China. Diagn Microbiol Infect Dis 2000; 36:107-12.
155. Fung CP, Hu BS, Lee SC et al. Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: an island-wide surveillance study between 1996 and 1997. J Antimicrob Chemother 2000; 45: 49-55.
156. Hsueh PR, Liu YC, Shyr JM et al. Multicenter surveillance of antimicrobial resistance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan During the 1998-99 Respiratory Period. Antimicrob Agents Chemother 2000; 44: 1342-5.
157. Invasive Bacterial Infection Surveillance (IBIS) Group International Clinical Epidemiology Network. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Lancet 1999; 353: 1216-21.
158. Saha SK, Rikitomi N, Ruhulamin M et al. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae strains causing childhood infections in Bangladesh 1993 to 1997. J Clin Microbiol 1999; 37: 798-800.
159. Rehman N, Ahmad SI. Antibiotic susceptibility of Streptococcus pneumoniae in Karachi. JPMA J Pak Medical Assoc 2000; 50: 58-60.
160. Uwaydah M, Jradeh M, Shihab Z. Antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Lebanon. J Antimicrob Chemother 1996; 38: 283-6.
161. Turnidge JD, Bell JM, Collington PJ on behalf of the Pneumococcal Study Group. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Med J Austr 1999; 170: 152-5.
162. Tee NW, Lin RV. Serotypes and antimicrobial resistance in Haemophilus influenzae in a hospital practice. Ann Acad Med Singapore 1996; 25: 184-7.
163. Ohkusu K, Nakamura A, Sawada K. Antibiotic resistance among recent clinical isolates of Haemophilus influenzae in Japanese children. Diagn Microbiol Infect Dis 2000; 36: 249-54.
164. Seki H, Kasahara Y, Ohta K et al. Increasing prevalence of ampicillin-resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy 1999; 45: 15-21.
165. McGee L, Klugman KP, Friedland D, Lee HJ. Spread of the Spanish multi-resistant serotype 23F clone of Streptococcus pneumoniae to Seoul, Korea. Microb Drug Resist 1997; 3: 253-7.
166. Baquero F. Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microb Drug Res 1995; 1: 115-20.
167. Feki-Berrajah L, Mahjoubi-Rhimi F, Karray-Hakim H et al. Streptococcus pneumoniae of lesser sensitivity to penicillin in the Sfax region, Tunisia (1994-1995) [in French]. Pathol Biol (Paris) 1998; 46: 331-4.
168. Ostroff SM, Harrison LH, Khallaf N et al. Resistance patterns of Streptococcus pneumoniae and Haemophilus influenzae isolates recovered in Egypt from patients with pneumonia. The Antimicrobial Resistance Surveillance Group Study Group. Clin Infect Dis 1996; 23: 1069-74.
169. Ohene A. Bacterial pathogens and their antimicrobial susceptibility in Kumasi, Ghana. East Afr Med J 1997; 74: 450-5.
170. O'Dempsey TJ, McArdle TF, Lloyd-Evans N et al. Pneumococcal disease among children in a rural area of West Africa. Pediatr Infect Dis J 1996; 15: 431-7.
171. Ringertz S, Muhe L, Krantz I et al. Prevalence of potential respiratory disease bacteria in children in Ethiopia. Antimicrobial susceptibility of the pathogens and use of antibiotics among the children. Acta Paediatr 1993; 82: 843-8.
172. Muhe L, Klugman K. Pneumococcal and Haemophilus influenzae meningitis in a children's hospital in Ethiopia: serotypes and susceptibility patterns. Trop Med Int Health 1999; 4: 421-7.
173. Paul J, Bates J, Kimari J et al. Serotypes and antibiotic susceptibilities of Streptococcus pneumoniae in Nairobi, Kenya. J Infect 1996; 32: 139-42.
174. Rowe AK, Deming MS, Schwartz B et al. Antimicrobial resistance of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in the Central African Republic. Pediatr Infect Dis J 2000; 19: 438-44.
175. Bogaerts J, Lepage P, Taelman H et al. Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from Rwanda, 1984-1990. J Infect 1993; 27: 157-68.
176. Woolfson A, Huebner R, Wasas A et al. Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. Bull World Health Organ 1997; 75: 453-62.
177. Huebner RE, Wasas A, Mushi A et al. Nasopharyngeal carriage and antimicrobial resistance in isolates of Streptococcus pneumoniae and Haemophilus influenzae type b in children under 5 years of age in Botswana. Int J Infect Dis 1998; 3: 18-25.
178. Simango C, Mvududu F. Penicillin resistant Streptococcus pneumoniae isolates in Harare, Zimbabwe. Cent Afr J Med 1999; 45: 100-2.
179. Klugman KP, Koornhof HJ. Drug resistant patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986. J Infect Dis 1988; 158: 956-64.
180. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146: 920-3.
181. Paul J. HIV and pneumococcal disease in Africa. Microbiological aspects. Trans R Soc Trop Med Hyg 1997; 91: 632-7.
182. Crewe-Brown HH, Karstaedt AS, Saunders GL et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997; 25: 1165-72.
183. Jones N, Huebner R, Khoosal M et al. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12: 2177-84.
184. Feldman C, Glatthaar M, Morar R et al. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest 1999; 116: 107-14.
185. Osoagbaka OU. In-vitro susceptibility patterns of some major respiratory tract pathogens in Nigeria to eleven selected antibiotics. West Afr Med J 1990; 9: 264-71.
186. Onyemelukwe NF. Haemophilus influenzae meningitis in parts of eastern Nigeria. E Afr Medical J 1994; 71: 129-31.
187. Ndip RN, Obi MC, Obi CL et al. Antibiogram of bacterial isolates from cases of otitis media and lower respiratory tract infections. Afr J Med Med Sci 1995; 24: 353-7.
188. Bijlmer HA, van Alphen L, Greenwood BM et al. Antibiotic susceptibility of invasive and noninvasive isolates of Haemophilus influenzae from the Gambia, West Africa. J Antimicrob Chemother 1994; 34: 275-80.
189. Hussey G, Hitchcock J, Hanslo D et al. Serotypes and antimicrobial susceptibility of Haemophilus influenzae. J Antimicrob Chemother 1994; 34: 1031-103.
190. Liebowitz LD, Klugman KP, Saunders J, Koornhof HJ. Serotype and antimicrobial susceptibility patterns of Haemophilus influenzae isolates from inpatients and outpatients in Johannesburg. S Afr Med J 1989; 76: 325-8.
191. Feldman C, Smith C, Kaka S, De Jong P, Promnitz DA. The clinical significance of Haemophilus influenzae and H. parainfluenzae isolated from the sputum of adult patients at an urban general hospital. S Afr Med J 1992; 81: 495-8.
192. Mthwalo M, Wasas A, Huebner R et al. Antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Lesotho. Bull World Health Organ 1998; 76: 641-50.